赵帅,陈蓉,曹家豪,王嘉仪,汪钦,陈彤,朱伯达,王紫薇,李成祥,廉坤

• 1:中国人民解放军空军军医大学第一附属医院心内科
• 2:西北大学生命科学学院
• 3:陕西中医药大学公共卫生学院
• 4:空军军医大学基础医学院学员队

摘要(Abstract)：

目的 评价经皮冠状动脉介入治疗（PCI）对冠状动脉慢性完全闭塞（CTO）病变合并左心室射血分数（LVEF）降低患者术后1个月和1年的生活质量的影响。方法 前瞻性连续性纳入2018年3月至2020年3月因冠心病诊断入院计划行冠状动脉造影的患者，术前48 h采用健康相关生命质量SF-12量表（SF-12）和西雅图心绞痛量表（SAQ）评价患者生活质量，同时收集记录患者临床基线资料。将造影诊断为CTO病变且成功行PCI的563例患者纳入本研究，依据术前LVEF，分为LVEF≥50%组（327例）和LVEF<50%组（236例）。术后1个月和1年分别对患者进行电话随访，记录患者主要不良心血管事件（MACE）的发生情况，同时采用SF-12和SAQ评价患者术后生活质量。结果 术后1个月，LVEF<50%组患者MACE发生率与LVEF≥50%组比较，差异无统计学意义（P=0.223）。术后1年，LVEF<50%组患者MACE发生率显著高于LVEF≥50%组（22.5%比10.4%,P<0.001），差异有统计学意义。术后1个月和1年时，两组患者的纽约心脏病协会（NYNA）心功能都发生了明显改善（均P<0.001）。术后1个月、术后1年LVEF≥50%组患者分别与术前比较，SF-12的生理领域得分均显著升高（均P<0.001）,SAQ 5个维度的得分均显著增加（均P<0.001）；术后1个月、术后1年LVEF<50%组患者分别与术前比较，SF-12的生理领域得分均显著升高（均P<0.001）,SAQ的5个维度的得分均显著增加（均P<0.001）。两组患者术后1个月、术后1年SF-12和SAQ的5个维度得分比较，差异均无统计学意义（均P>0.05）。结论 成功PCI可以显著改善CTO病变合并LVEF降低患者术后1个月和1年的心功能和生活质量。

关键词(KeyWords)： 冠状动脉慢性完全闭塞;左心室射血分数;经皮冠状动脉介入治疗;生活质量

Abstract:

Keywords:

基金项目(Foundation): 白求恩-默克糖尿病研究基金项目（G2017044）;; 西京医院临床新技术新业务项目（XJGX15Y39）;; 西安市科技计划项目（20YXYJ0003）

作者(Author): 赵帅,陈蓉,曹家豪,王嘉仪,汪钦,陈彤,朱伯达,王紫薇,李成祥,廉坤

参考文献(References)：

• [1] Ybarra LF, Rinfret S, Brilakis ES, et al. Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies:CTO-ARC Consensus Recommendations[J].Circulation, 2021, 143(5):479-500.
• [2] Christof ferson RD, Lehmann KG, Martin GV, et al. Ef fect of chronic total coronary occlusion on treatment strategy[J]. Am J Cardiol, 2005, 95(9):1088-1091.
• [3] Fefer P, Knudtson ML, Cheema AN, et al. Current perspectives on coronary chronic total occlusions:the canadian multicenter chronic total occlusions registry[J]. J Am Coll Cardiol, 2012, 59(11):991-997.
• [4] Jeroudi OM, Alomar ME, Michael TT, et al. Prevalence and management of coronary chronic total occlusions in a tertiary veterans af fairs hospital[J]. Catheter Cardiovasc Interv, 2014,84(4):637-643.
• [5] Werner GS, Gitt AK, Zeymer U, et al. Chronic total coronary occlusions in patients with stable angina pectoris:impact on therapy and outcome in present day clinical practice[J]. Clin Res Cardiol, 2009, 98(7):435-441.
• [6] Tsai TT, Stanislawski MA, Shunk KA, et al. Contemporary incidence, management, and long-term outcomes of percutaneous coronary interventions for chronic coronary artery total occlusions:insights from the VA CART program[J].JACC Cardiovasc Interv, 2017, 10(9):866-875.
• [7] Maeremans J, Walsh S, Knaapen P, et al. The hybrid algorithm for treating chronic total occlusions in europe:the RECHARGE registry[J]. J Am Coll Cardiol, 2016, 68(18):1958-1970.
• [8] Christopoulos G, Kandzari DE, Yeh RW, et al. Development and validation of a novel scoring system for predicting technical success of chronic total occlusion percutaneous coronary interventions:the PROGRESS CTO(Prospective Global Registry for the Study of Chronic Total Occlusion Intervention)Score[J]. JACC Cardiovasc Interv, 2016, 9(1):1-9.
• [9] Chan CY, Wu EB, Yan BP, et al. Procedure failure of chronic total occlusion percutaneous coronary intervention in an algorithm driven contemporary Asia-Pacific Chronic Total Occlusion Club(APCTO Club)multicenter registry[J]. Catheter Cardiovasc Interv, 2019, 93(6):1033-1038.
• [10] Hannan EL,Racz M,Holmes DR,et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era[J]. Circulation,2006,113(20):2406-2412.
• [11] Hannan EL, Wu C, Walford G, et al. Incomplete revascularization in the era of drug-eluting stents:impact on adverse outcomes[J].JACC Cardiovasc Interv, 2009, 2(1):17-25.
• [12] Seiler C. Assessment and impact of the human coronary collateral circulation on myocardial ischemia and outcome[J]. Circ Cardiovasc Interv, 2013, 6(6):719-728.
• [13] Tajstra M, Pyka L, Gorol J, et al. Impact of chronic total occlusion of the coronary artery on long-term prognosis in patients with ischemic systolic heart failure:insights from the COMMIT-HF Registry[J].JACC Cardiovasc Interv, 2016, 9(17):1790-1797.
• [14] Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey:construction of scales and preliminary tests of reliability and validity[J]. Med Care, 1996, 34(3):220-233.
• [15] Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle angina questionnaire:a new functional status measure for coronary artery disease[J]. J Am Coll Cardiol,1995, 25(2):333-341.
• [16] Tsao CW, Preis SR, Peloso GM, et al. Relations of longterm and contemporary lipid levels and lipid genetic risk scores with coronary artery calcium in the framingham heart study[J]. J Am Coll Cardiol,2012, 60(23):2364-2371.
• [17] Duncan MS, Vasan RS, Xanthakis V. Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all-cause mortality:observations from the framingham study over35 years[J]. J Am Heart Assoc,2019, 8(11):e011433.
• [18] Szarek M, Bittner VA, Aylward P, et al. Lipoprotein(a)lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering:ODYSSEY OUTCOMES trial[J]. Eur Heart J,2020, 41(44):4245-4255.
• [19] Kook H, Yang JH, Cho JY, et al. Dif ferential clinical impact of chronic total occlusion revascularization based on left ventricular systolic function[J]. Clin Res Cardiol,2021, 110(2):237-248.
• [20] Galassi AR, Boukhris M, Toma A, et al. Percutaneous coronary intervention of chronic total occlusions in patients with low left ventricular ejection fraction[J]. JACC Cardiovasc Interv,2017, 10(21):2158-2170.
• [21] Lee SW, Lee PH, Ahn JM,et al. Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion[J]. Circulation,2019,139(14):1674-1683.
• [22] Safl ey DM, Grantham JA, Hatch J, et al. Quality of life benefi ts of percutaneous coronary intervention for chronic occlusions[J].Catheter Cardiovasc Interv,2014, 84(4):629-634.
• [23]赵帅，王伟，汪钦，等. PCI治疗对CTO合并LVEF降低的冠心病患者术后短期生活质量的影响[J].中国动脉硬化杂志，2019,27(7):593-598.